Pfizer to begin clinical trials for a COVID-19 shot targeting Delta variant

  • Pfizer (NYSE:PFE) and its partner BioNTech (NASDAQ:BNTX) are planning to begin clinical studies for an updated version of their COVID-19 vaccine to target the Delta variant of the virus, Financial Times reports. In the post-market, the shares of the two vaccine makers are rising on the news.
  • Pfizer and BioNTech are in talks with the U.S. regulators over plans for the clinical trial which is expected to begin in August.
  • 'While we believe a third dose of [our vaccine] has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, we are remaining vigilant and are developing an updated version of the Pfizer-Covid-19 vaccine," Pfizer noted.
  • The development is likely to garner attention amid concerns over the efficacy of the current generation of COVID-19 vaccines as the prevalence of highly transmissible Delta variant rises.

    Over the current book year the total revenue from the company in New York City will be 73.51 billion USD (consensus estimates). This is rather significant more than 2021's revenue of 41.91 billion USD.

    Historical revenues and results Pfizer plus estimates 2021

    financiële analyse

    The analysts expect for 2021 a net profit of 21.19 billion USD. For this year the consensus of the result per share is a profit of 3.73 USD. The price/earnings-ratio therefore equals 11.01.

    Huge dividend Pfizer

    Per share the analysts are expecting a dividend of 1.58 USD per share. Pfizer 's dividend yield thus equals 3.85 percent. The average dividend yield of the pharmaceutical companies equals a moderate 1.39 percent.

    Pfizer 's market capitalization is around 227.17 billion USD. 23

    Historical stock prices Pfizer period 2007-2021

    fundamental data pfizer

    At 21.24 the stock trades 0 percent lower at 41.05 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.